Ammonium chloride, also known as NH4Cl, is a widely used compound in the medical field. It is typically used as a buffer, to neutralize acidity in a solution, and as an electrolyte in medical solutions. It is also used in pharmaceuticals, as a preservative and as a stabilizer. Despite its widespread use, the potential of NH4Cl has yet to be fully explored. This article will explore the potential of NH4Cl, looking at its possible applications in medical treatments and other uses.
NH4Cl is a white, crystalline salt, with a molecular weight of 53.49 g/mol and a density of 1.527 g/cm3. It is highly soluble in water, with a solubility of 1.6 g/100 ml, and is also soluble in alcohols and other organic solvents. It is a weak acid, with a pKa of 9.25, and is readily hydrolyzed in water. It is also hygroscopic, meaning it absorbs moisture from the air.
NH4Cl is used in the medical field for a variety of purposes. It is used as a buffer, to neutralize acidity in a solution, and as an electrolyte in medical solutions. It is also used in pharmaceuticals, as a preservative and as a stabilizer. It is also used in the treatment of certain medical conditions, such as hypokalemia, hyperkalemia, and metabolic acidosis.
Despite its widespread use, the potential of NH4Cl has yet to be fully explored. Research has shown that NH4Cl has potential applications in the medical field, such as in the treatment of cancer, as a wound healing agent, and as an anti-inflammatory agent.
Research has shown that NH4Cl may have potential applications in the treatment of cancer. In one study, NH4Cl was found to inhibit the growth of human breast cancer cells in vitro. In another study, NH4Cl was found to inhibit the growth of human liver cancer cells in vitro. The mechanism of action is not yet clear, but it is thought to involve the inhibition of cell proliferation and the induction of apoptosis.
NH4Cl has also been studied for its potential use as a wound healing agent. In one study, NH4Cl was found to improve wound healing in animal models. The mechanism of action is not yet clear, but it is thought to involve the stimulation of collagen synthesis and the promotion of angiogenesis.
NH4Cl has also been studied for its potential use as an anti-inflammatory agent. In one study, NH4Cl was found to reduce inflammation in animal models. The mechanism of action is not yet clear, but it is thought to involve the inhibition of pro-inflammatory cytokines.
NH4Cl is a widely used compound in the medical field, used as a buffer, electrolyte, preservative, and stabilizer. Despite its widespread use, the potential of NH4Cl has yet to be fully explored. Research has shown that NH4Cl may have potential applications in the medical field, such as in the treatment of cancer, as a wound healing agent, and as an anti-inflammatory agent. Further research is needed to explore the potential of NH4Cl in these and other applications.
1.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
2.
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors
3.
A promising medication could slow brain tumors in children.
4.
If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version
5.
A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.
1.
Deterministic Reprogramming of Neutrophils within Tumors: A New Frontier in Cancer Research
2.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
3.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
4.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
5.
Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation